Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Efficacy of standard treatment in patients with Hodgkin's disease - A single center experience
Autore:
Geissler, K; Gisslinger, H; Knobl, P; Sperr, W; Valent, P; Dieckmann, K; Chott, A; Potter, R; Lechner, K; Jager, U;
Indirizzi:
Univ Vienna, Innere Med Klin 1, Klin Abt Hamatol & Hamostaseol, Vienna, Austria Univ Vienna Vienna Austria n Abt Hamatol & Hamostaseol, Vienna, Austria Univ Vienna, Klin Strahlentherapie & Strahlenbiol, Klin Abt Teletherapie, Vienna, Austria Univ Vienna Vienna Austria biol, Klin Abt Teletherapie, Vienna, Austria Allgemeines Krankenhaus Wien, Klin Abt Pathol Anat & Histol, Vienna, Austria Allgemeines Krankenhaus Wien Vienna Austria t & Histol, Vienna, Austria
Titolo Testata:
WIENER KLINISCHE WOCHENSCHRIFT
fascicolo: 14, volume: 112, anno: 2000,
pagine: 624 - 628
SICI:
0043-5325(20000728)112:14<624:EOSTIP>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
TERM FOLLOW-UP; COMBINATION CHEMOTHERAPY; MOPP; MALIGNANCIES; LEUKEMIA;
Keywords:
standard treatment; Hodgkin's disease;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
16
Recensione:
Indirizzi per estratti:
Indirizzo: Geissler, K Allgemeines Krankenhaus Wien, Klin Abt Hamatol & Hamostaseol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria Allgemeines Krankenhaus WienWahringer Gurtel 18-20 Vienna Austria A-1090
Citazione:
K. Geissler et al., "Efficacy of standard treatment in patients with Hodgkin's disease - A single center experience", WIEN KLIN W, 112(14), 2000, pp. 624-628

Abstract

Sixty-two consecutive patients with newly diagnosed Hodgkin's Disease (HD)were treated at our institution between 1991 and 1998 in accordance with protocols which we considered as optimal standard therapy. In patients with localised disease, extended field irradiation alone was used initially but short duration chemotherapy followed by involved field irradiation was given later. Initially, MOPP/ABV chemotherapy was considered the standard treatment regimen for advanced HD, subsequently it was replaced by ABVD treatment. At 5 years patients with localised HD have a projected overall survival of 95% and a failure-free survival of 72%. Relapses in patients treated with radiotherapy alone (6/16 cases) could be successfully managed with chemotherapy in most cases (5/6). In advanced HD, projected 5-year survival and failure-free survival are 100% and 80%, respectively. No treatment-related deaths or secondary malignancies were registered.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/09/20 alle ore 12:00:00